The evolving regulatory role of ubiquitin-editing enzyme A20 in psoriasis during calcipotriol treatment

Dyring‐Andersen, Beatrice

doi:10.1111/bjd.14656

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[49] showed that TNFAIP3 protein is over-expressed under psoriatic inflammation, favoring keratinocyte proliferation and suppressing apoptosis. This strong expression of TNFAIP3 found in lesional psoriatic skin has been posited to inhibit the NF-κB pathway; however, a strong expression of NF-κB was observed [49], suggesting that TNFAIP3 is disabled or dysfunctional in patients with psoriasis [50]. It is worth mentioning that in psoriatic patients with higher TNFAIP3 expression levels in their skin lesions compared to normal controls, calcipotriol (a vitamin D3 analogue) therapy significantly reduced the expression levels of both TNFAIP3 and NF-κB [49, 51].…”

Section: Discussionmentioning

confidence: 99%

Low TNFAIP3 expression in psoriatic skin promotes disease susceptibility and severity

2019

View full text Add to dashboard Cite

Psoriasis vulgaris is a systemic disorder with an underlying immune dysregulation that predisposes to inflammatory skin lesions. Meanwhile, tumor necrosis factor alpha-induced protein 3 (TNFAIP3) has been described as a protective molecule against the deleterious effects of uncontrolled inflammation. In this study, we compared the expression levels of TNFAIP3 in blood and psoriatic skin biopsies from psoriatic patients versus those in normal individuals. Additionally, the levels of TNFAIP3 protein in psoriatic skin biopsies were compared to those in normal individuals. Thirty psoriatic patients and 30 healthy participants (control group) were enrolled. The expression levels of TNFAIP3 in blood and skin were measured by quantitative reverse transcription PCR, while the skin levels of TNFAIP3 protein were measured by western blot. Psoriatic patients showed significantly lower expression levels of TNFAIP3 in psoriatic skin and blood ( P < 0.001) as well as of TNFAIP3 protein in psoriatic skin ( P < 0.001) compared to controls. A significant lower expression of TNFAIP3 and TNFAIP3 protein in psoriatic skin was detected in moderate/severe cases compared to mild cases ( P = 0.004 and 0.003 respectively). Moreover, a significant negative correlation was found between TNFAIP3 mRNA in psoriatic tissue and psoriasis area severity index values (r s = -0.382, P- value = 0.037). In conclusion, TNFAIP3 may serve as a predictive and prognostic biomarker in psoriatic patients. Enhancing the expression and/or function of TNFAIP3 in the affected cell type may be a promising therapeutic strategy.

show abstract